Bioptimus has partnered with Cancer Research Horizons to access S:CORT, one of the most comprehensive multimodal colorectal cancer datasets. The agreement brings the first UK cohort into STELA, adding over 1,750 patient profiles.
Bioptimus has partnered with Cancer Research Horizons to access S:CORT, one of the most comprehensive multimodal colorectal cancer datasets. The agreement brings the first UK cohort into STELA, adding over 1,750 patient profiles.
Bioptimus has partnered with Cancer Research Horizons to access S:CORT, one of the most comprehensive multimodal colorectal cancer datasets. The agreement brings the first UK cohort into STELA, adding over 1,750 patient profiles.
Bioptimus has partnered with Cancer Research Horizons to access S:CORT, one of the most comprehensive multimodal colorectal cancer datasets. The agreement brings the first UK cohort into STELA, adding over 1,750 patient profiles.
Bioptimus has partnered with Cancer Research Horizons to access S:CORT, one of the most comprehensive multimodal colorectal cancer datasets. The agreement brings the first UK cohort into STELA, adding over 1,750 patient profiles.
Bioptimus has signed a partnership with the Fédération Francophone de Cancérologie Digestive (FFCD) granting access to clinical trial data from over 3,000 gastrointestinal (GI) cancer patients, which will feed into STELA (Spatial Tissue Embedding Learning Atlas), its initiative to build the world's largest clinically linked multimodal tissue atlas. The deal incorporates spatial transcriptomics and omics data into Bioptimus's M-Optimus multimodal foundation model for precision oncology, supporting STELA's goal of profiling 100,000 specimens across a global research network.
Bioptimus has signed a partnership with the Fédération Francophone de Cancérologie Digestive (FFCD) granting access to clinical trial data from over 3,000 gastrointestinal (GI) cancer patients, which will feed into STELA (Spatial Tissue Embedding Learning Atlas), its initiative to build the world's largest clinically linked multimodal tissue atlas. The deal incorporates spatial transcriptomics and omics data into Bioptimus's M-Optimus multimodal foundation model for precision oncology, supporting STELA's goal of profiling 100,000 specimens across a global research network.
Bioptimus has signed a partnership with the Fédération Francophone de Cancérologie Digestive (FFCD) granting access to clinical trial data from over 3,000 gastrointestinal (GI) cancer patients, which will feed into STELA (Spatial Tissue Embedding Learning Atlas), its initiative to build the world's largest clinically linked multimodal tissue atlas. The deal incorporates spatial transcriptomics and omics data into Bioptimus's M-Optimus multimodal foundation model for precision oncology, supporting STELA's goal of profiling 100,000 specimens across a global research network.
Bioptimus has signed a partnership with the Fédération Francophone de Cancérologie Digestive (FFCD) granting access to clinical trial data from over 3,000 gastrointestinal (GI) cancer patients, which will feed into STELA (Spatial Tissue Embedding Learning Atlas), its initiative to build the world's largest clinically linked multimodal tissue atlas. The deal incorporates spatial transcriptomics and omics data into Bioptimus's M-Optimus multimodal foundation model for precision oncology, supporting STELA's goal of profiling 100,000 specimens across a global research network.
Bioptimus has signed a partnership with the Fédération Francophone de Cancérologie Digestive (FFCD) granting access to clinical trial data from over 3,000 gastrointestinal (GI) cancer patients, which will feed into STELA (Spatial Tissue Embedding Learning Atlas), its initiative to build the world's largest clinically linked multimodal tissue atlas. The deal incorporates spatial transcriptomics and omics data into Bioptimus's M-Optimus multimodal foundation model for precision oncology, supporting STELA's goal of profiling 100,000 specimens across a global research network.
The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world today.
The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world today.
The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world today.
The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world today.
The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world today.
Bioptimus, the leader in AI models for biology, today announced a major leap forward with the unveiling of M-Optimus, the first model that combines multiple biological modalities, designed to simulate biology in its full complexity. The company is offering early access to a limited number of pioneer clients, while simultaneously enhancing access to its world-leading pathology model, H-Optimus-1, through a partnership and limited-time offer with Amazon SageMaker AI.
Bioptimus, the leader in AI models for biology, today announced a major leap forward with the unveiling of M-Optimus, the first model that combines multiple biological modalities, designed to simulate biology in its full complexity. The company is offering early access to a limited number of pioneer clients, while simultaneously enhancing access to its world-leading pathology model, H-Optimus-1, through a partnership and limited-time offer with Amazon SageMaker AI.
Bioptimus, the leader in AI models for biology, today announced a major leap forward with the unveiling of M-Optimus, the first model that combines multiple biological modalities, designed to simulate biology in its full complexity. The company is offering early access to a limited number of pioneer clients, while simultaneously enhancing access to its world-leading pathology model, H-Optimus-1, through a partnership and limited-time offer with Amazon SageMaker AI.
Bioptimus, the leader in AI models for biology, today announced a major leap forward with the unveiling of M-Optimus, the first model that combines multiple biological modalities, designed to simulate biology in its full complexity. The company is offering early access to a limited number of pioneer clients, while simultaneously enhancing access to its world-leading pathology model, H-Optimus-1, through a partnership and limited-time offer with Amazon SageMaker AI.
Bioptimus, the leader in AI models for biology, today announced a major leap forward with the unveiling of M-Optimus, the first model that combines multiple biological modalities, designed to simulate biology in its full complexity. The company is offering early access to a limited number of pioneer clients, while simultaneously enhancing access to its world-leading pathology model, H-Optimus-1, through a partnership and limited-time offer with Amazon SageMaker AI.
Eight internationally renowned experts join Bioptimus to pioneer large-scale foundation models that will transform science and medicine
Eight internationally renowned experts join Bioptimus to pioneer large-scale foundation models that will transform science and medicine
Eight internationally renowned experts join Bioptimus to pioneer large-scale foundation models that will transform science and medicine
Eight internationally renowned experts join Bioptimus to pioneer large-scale foundation models that will transform science and medicine
Eight internationally renowned experts join Bioptimus to pioneer large-scale foundation models that will transform science and medicine
Ketan Patel and Tokuwa Kanno bring deep user, product, and scientific expertise to accelerate real-world applications of Bioptimus’ foundation model for biology.
Ketan Patel and Tokuwa Kanno bring deep user, product, and scientific expertise to accelerate real-world applications of Bioptimus’ foundation model for biology.
Ketan Patel and Tokuwa Kanno bring deep user, product, and scientific expertise to accelerate real-world applications of Bioptimus’ foundation model for biology.
Ketan Patel and Tokuwa Kanno bring deep user, product, and scientific expertise to accelerate real-world applications of Bioptimus’ foundation model for biology.
Ketan Patel and Tokuwa Kanno bring deep user, product, and scientific expertise to accelerate real-world applications of Bioptimus’ foundation model for biology.
Industry veteran brings deep expertise in biotech commercialization and pharma partnerships to advance foundation model for biology
Industry veteran brings deep expertise in biotech commercialization and pharma partnerships to advance foundation model for biology
Industry veteran brings deep expertise in biotech commercialization and pharma partnerships to advance foundation model for biology
Industry veteran brings deep expertise in biotech commercialization and pharma partnerships to advance foundation model for biology
Industry veteran brings deep expertise in biotech commercialization and pharma partnerships to advance foundation model for biology
Through DGX Cloud Lepton and collaboration with Sofinnova Partners, Bioptimus gains critical AI infrastructure to scale biological model training
Through DGX Cloud Lepton and collaboration with Sofinnova Partners, Bioptimus gains critical AI infrastructure to scale biological model training
Through DGX Cloud Lepton and collaboration with Sofinnova Partners, Bioptimus gains critical AI infrastructure to scale biological model training
Through DGX Cloud Lepton and collaboration with Sofinnova Partners, Bioptimus gains critical AI infrastructure to scale biological model training
Through DGX Cloud Lepton and collaboration with Sofinnova Partners, Bioptimus gains critical AI infrastructure to scale biological model training
The official announcement was made today by Clara Chappaz, Minister for Digital Affairs and Artificial Intelligence.
The official announcement was made today by Clara Chappaz, Minister for Digital Affairs and Artificial Intelligence.
The official announcement was made today by Clara Chappaz, Minister for Digital Affairs and Artificial Intelligence.
The official announcement was made today by Clara Chappaz, Minister for Digital Affairs and Artificial Intelligence.
The official announcement was made today by Clara Chappaz, Minister for Digital Affairs and Artificial Intelligence.
This launch gives healthcare and life sciences organizations immediate access to deploy Bioptimus’s cutting-edge pathology model in their own secure cloud environments.
This launch gives healthcare and life sciences organizations immediate access to deploy Bioptimus’s cutting-edge pathology model in their own secure cloud environments.
This launch gives healthcare and life sciences organizations immediate access to deploy Bioptimus’s cutting-edge pathology model in their own secure cloud environments.
This launch gives healthcare and life sciences organizations immediate access to deploy Bioptimus’s cutting-edge pathology model in their own secure cloud environments.
This launch gives healthcare and life sciences organizations immediate access to deploy Bioptimus’s cutting-edge pathology model in their own secure cloud environments.
Mathilda joins Bioptimus with an extensive track record in building pioneering businesses and a reputation as a leader in scaling impactful organizations globally.
Mathilda joins Bioptimus with an extensive track record in building pioneering businesses and a reputation as a leader in scaling impactful organizations globally.
Mathilda joins Bioptimus with an extensive track record in building pioneering businesses and a reputation as a leader in scaling impactful organizations globally.
Mathilda joins Bioptimus with an extensive track record in building pioneering businesses and a reputation as a leader in scaling impactful organizations globally.
Mathilda joins Bioptimus with an extensive track record in building pioneering businesses and a reputation as a leader in scaling impactful organizations globally.
Bioptimus will connect the different scales of biology with generative AI
Bioptimus will connect the different scales of biology with generative AI
Bioptimus will connect the different scales of biology with generative AI
Bioptimus will connect the different scales of biology with generative AI
Bioptimus will connect the different scales of biology with generative AI
